The potential efficacy of apelixin in domestic applications

Alpelisib (Alpelisib), an innovative HER2-positive breast cancer targeted drug, has not yet appeared in China, but its combination therapy with fulvestrant has shown good therapeutic effects overseas for patients with locally advanced and metastatic HER2-positive breast cancer who are resistant to endocrine therapy or unsuitable for chemotherapy.

Based on data from a series of clinical studies, this combination treatment showed clear advantages over fulvestrant alone on several key evaluation points. Specifically, patients' progression-free survival (PFS) was significantly extended and their risk of disease progression was greatly reduced. Especially for those patient groups who still face challenges after multiple treatments - whose tumors are HR-positive, HER2-negative and have PIK3CA mutations - the effect of apelvis is particularly significant.

Because each patient’s physical condition, disease history, and genetic characteristics are different, so will the response to treatment with Apelvis. Apelvis is generally better tolerated by patients than traditional chemotherapy drugs. This is further supported by evidence from large phase III clinical studies, which showed that apelvis can significantly improve the clinical benefit rate of patients, and the side effects are generally within the control range, although some patients may experience mild to moderate skin reactions or diarrhea.

As a precise targeted therapy, the efficacy of apelvis may vary depending on the patient's genetic differences. Therefore, it is critical to conduct comprehensive genetic testing to determine whether a patient has a PIK3CA mutation before using this drug. This not only helps doctors develop personalized treatment plans to improve treatment effects, but also ensures more precise and efficient drug use.